Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.

Eur J Haematol · 2021 · PMC8457079 · PMID 34053123

Europe PMC DOI

hedged sentences

0.1030

closest p · 2.1× alpha

0.1030

boldest claim

The sentences

did not reach statistical significanceP = .103not close (p > 0.1)

A higher proportion of CLL‐1 bimodality was observed in patients with monosomal karyotype compared to other cytogenetic risk groups (41% vs 16%‐33%, respectively), but this did not reach statistical significance P = .103 (Figure 2C ).

also in 111,027 other papers

showed a trendno p-value reported

CD34 + CLL‐1 + cells showed a trend of having a higher median percentage on mature markers such as CD38, CD33, HLA‐DR, CD15, and CD123 positivity whereas CD34 + CLL‐1 − cells had a higher percentage of CD38 negativity (Figure 4C‐I & Figure S7 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.